This article is more than 5 years old. Information may no longer be current.

Fera Pharmaceuticals acquires Fougera ophthalmic ointment product line

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Fera Pharmaceuticals has announced the acquisition of seven abbreviated new drug applications marketed by Fougera, which is a division of Nycomed US.

Fera will accept orders for and begin shipment of Bacitracin under the Fougera label in September. In early 2010, Fera expects to complete all necessary technical transfers and regulatory approvals for shipment of Bacitracin under its own label, the company said in a release.

In the acquisition, Fera also received all rights, title and interest to Bacitracin Zinc and Polymyxin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and Dexamethasone; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Acetate; and Erythromycin Ophthalmic Ointments USP.

According to the release, the seven products accounted for 80% of the ophthalmic ointment market volume in 2008.